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Abstract
Despite significant treatment advances over the past decade, metastatic gastrointestinal stromal
tumor (GIST) remains largely incurable. Rare diseases, such as GIST, individually affect small
groups of patients but collectively are estimated to affect 25–30 million people in the U.S. alone.
Given the costs associated with the discovery, development and registration of new drugs, orphan
diseases such as GIST are often not pursued by mainstream pharmaceutical companies. As a
result, “drug repurposing” or “repositioning”, has emerged as an alternative to the traditional drug
development process. In this study we screened 796 FDA-approved drugs and found that two of
these compounds, auranofin and fludarabine phosphate, effectively and selectively inhibited the
proliferation of GISTs including imatinib-resistant cells. One of the most notable drug hits,
auranofin (Ridaura®), an oral, gold-containing agent approved by the FDA in 1985 for the
treatment of rheumatoid arthritis (RA), was found to inhibit thioredoxin reductase (TrxR) activity
and induce reactive oxygen species (ROS) production, leading to dramatic inhibition of GIST cell
growth and viability. Importantly, the anti-cancer activity associated with auranofin was
independent of IM resistant status, but was closely related to the endogenous and inducible levels
of ROS, therefore is prior to IM response. Coupled with the fact auranofin has an established
safety profile in patients, these findings suggest for the first time that auranofin may have clinical
benefit for GIST patients, particularly in those suffering from imatinib-resistant and recurrent
forms of this disease.
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Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal malignancies
of the digestive tract with an estimated annual incidence of ~6,000 new cases in the United
States (1). Approximately ~85% of GISTs contain somatic activating mutations in one of
two proto-oncogenes: KIT or PDGFRA, which encode the tyrosine kinase receptors c-KIT
and the platelet-derived growth factor receptor α, respectively (2–4). More recently,
mutations in the serine-threonine kinase BRAF have been identified in a very small number
of GISTs (5, 6).
Historically, there were few safe and effective therapeutic options for long-term GIST
treatment and disease maintenance due to the ineffectiveness of radiation and cytotoxic
chemotherapy. The clinical outlook for adults with GIST improved radically following the
discovery that this malignancy is most commonly driven by signaling via the c-KIT
receptor, which can be inhibited by small molecule tyrosine kinase inhibitors such as
imatinib (7–10). In a series of clinical trials, treatment of advanced-stage patients with
imatinib yielded objective response rates of 55–78%, with approximately half of patients
remaining disease-free for 2 years and median overall survival of approximately 50–55
months (11). Imatinib also delayed time to disease progression in the adjuvant setting, with a
trend toward improved overall survival. These data led FDA to approve imatinib for
treatment of advanced-stage GIST in 2002, and for use in the adjuvant setting in 2008.
Unfortunately, resistance to imatinib has been increasingly observed (8, 11–13). Resistance
to initial therapy, so-called `early' or `intrinsic' resistance, occurs in 10–20% of patients; late,
or `acquired' resistance, occurs in about 40% of patients. The molecular mechanisms of both
categories of resistance are being elucidated including secondary mutations in c-KIT or
PDGFR, leading to the introduction of newer kinase inhibitors targeting these additional
pathways into the clinic. However, it is now also clear that GIST cells can utilize complex,
redundant mechanisms to maintain aberrant signaling, which may confound therapy with
drugs targeting any particular kinase (4, 8, 14, 15).
Recently, a putative GIST stem cell (KITlowCd44+Cd34+) has been identified (16, 17).
These GIST stem cells, which have the potential to completely reconstitute tumors and
establish metastases, are inherently resistant to inhibitors of c-KIT and PDGFR. Thus, the
next generations of therapies for GIST will almost certainly have to include other drugs with
independent, potentially complementary mechanisms of action to currently-used kinase
inhibitors (18).
Costs associated with the discovery, development and registration of novel, new drugs have
been estimated in excess of $1.5 B and require 10–17 years to complete. As a result, rare or
orphan diseases such as GIST are often not pursued by large, for-profit pharmaceutical
companies. In recent years, drug repurposing, identifying new therapeutic applications for
FDA approved and abandoned drugs, has been demonstrated as a successful approach to
addressing the unmet medical needs of patients suffering from rare diseases. Novel
approaches to drug rediscovery, the identification of opportunities to evaluate FDA
approved and abandoned drugs for new therapeutic uses, have emerged. Patients gain access
to promising new therapies much more quickly by capitalizing on prior experience, resulting
in reduced drug development and registration cycle times and cost (19). By employing
repurposing and rediscovery strategies, drug development becomes affordable and
achievable by non-profit organizations including academia, government, and disease
philanthropy organizations, particularly through creative partnerships (20).
We report a drug repurposing approach to identify a potential drug for GIST patients.
Auranofin inhibits TrxR enzymatic activity and increases ROS production. Auranofin
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treatments lead to early and late apoptosis in GIST cells that result in cell death. In
summary, we have shown that inhibition of GIST cell proliferation and induction of
apoptosis by auranofin is dependent on drug-induced changes in ROS production.
MATERIALS AND METHODS
General Methods
All cell proliferation and caspase activity measurements were made on 384-well, black
μClear microplates (Greiner bio-one, Germany). All cell proliferation experiments were
assessed using the CellTiter-Blue® reagent according to the manufacturer's protocol
(Promega). All fluorescence or luminescence measurements were made using Infinite®
M200 Pro plate reader (Tecan, Switzerland). The fluorescence values are reported in relative
fluorescence units (RFU) and were measured at an excitation wavelength of 544 nm and an
emission wavelength of 590 nm. Data were normalized to percentage inhibition and IC50
concentrations were determined for each drug over a 72-h incubation period by the
SigmaPlot program (Systat Software).
Compound Library
The FDA-approved drug Library (provided by the Lead Development and Optimization
Shared Resource within the NCI Cancer Center at the University of Kansas) contains 796
drugs with known bioavailability and safety in humans. Compounds were present at 10 mM
in DMSO. The full list of drugs is provided in Table S1. For hit validation, IM was
purchased from the LC Laboratories and dissolved in sterile water. Fludarabine phosphate,
idarubicin HCl, and bortezomib were purchased from the Selleck Chemicals. All drugs
except IM were dissolved in DMSO.
Cell Culture
GIST-T1, a tumor cell line possessing a heterozygous mutation in KIT exon 11, was kindly
provided by Takahiro Taguchi and untransformed smooth muscle cell line ULTR cells were
purchased from ATCC and maintained in DMEM containing 10% fetal bovine serum (14).
GIST 882 cells (c-KIT exon 13 homozygous mutation) were gifted from Jonathan A
Fletcher and maintained in RPMI containing 15% fetal bovine serum (21, 22). GIST T1-10R
cells, derived in Dr. Godwin's laboratory, were maintained in DMEM containing 10% fetal
bovine serum and supplied with 10 μM IM to maintain drug resistance. IM was deleted from
the culture for indicated hours in experiments with GIST T1-10R cells. Hs 919.T. cells were
purchased from ATCC and maintained in DMEM containing 10% fetal bovine serum. All
cell lines were supplied with 1% penicillin/streptomycin and were maintained in a 5% CO2
atmosphere at 37 °C. Authentication for cell lines that were not purchased from ATCC was
carried out by the Clinical Molecular Oncology Laboratory (The University of Kansas
Cancer Center, KS USA).
Quantitative Drug Screen Assay
Drugs or vehicle (DMSO) were preloaded by the KU High Throughput Screen Laboratory
(KU HTSL) as 250 nL aliquots on an Echo550 platform to each well to give a final doses
range from 10 μM to 0.078 μM (serial twofold dilutions) in 25 μl in duplicates (38 plates
for each cell line). Cells were grown to 80% confluence, harvested and aliquoted into 384
well plates at concentrations of 1,000–1,500 cells per well in a total volume of 25 μl/well
with or without imatinib mesylate using a Matrix Wellmate (Thermo Scientific). The
imatinib mesylate concentrations used for the combination study were the IC30 values: 10
nM, 10 nM, and 40 nM for GIST-T1, GIST T1-10R, and GIST 882 cells respectively (data
not shown). Cells were cultured for 72 hours at 37 °C. Aliquots of 5 μl CellTiter-Blue®
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Reagent were added directly to each well, the plates were incubated at 37 °C for 3 h and the
fluorescent signal was measured. IM-treated (at established IC50 value for each cell line)
wells and vehicle only wells on each plate were uniformly distributed throughout the screen
and served as intraplate controls. Background plates containing vehicle only were inserted
throughout the screen as interplate controls. The controls were used to calculate the
background levels of the assay and to evaluate assay response as well as performance.
Performance of the assay was calculated and the Z' factors were ≥ 0.5 (23).
Drug Screen Assay in Hs 919.T. cell line
Drugs or vehicle (DMSO) were preloaded by the KU HTSL as 250 nL aliquots on an
Echo550 platform to each well to give a final dose of 1 μM in 25 μl. Cells were grown to
80% confluence, harvested and aliquoted into 384 well plates at concentrations of 750 cells
per well in a total volume of 25 μl/well using a Matrix Wellmate (Thermo Scientific). Cells
were cultured for 72 hours at 37 °C. 25 μl CellTiter-Glo® Reagent was added directly to
each well, the plates were incubated at room temperature for 15 min and the luminescence
signal was measured. Following subtraction of background counts, the percentage of growth
inhibition was calculated by dividing the value from drug-treated sample by that from
control well incubated in the absence of drug. Samples exhibiting >50% growth inhibition in
the presence of 1 μM drug were classified as positive hits.
TrxR Activity Measurement
Cells in log phase of growth were grown to 80% confluence, harvested and aliquoted into 6-
well plates at concentrations of 500,000 cells per well in a total volume of 1 ml/well. Cells
were allowed to attach overnight and were treated with or without auranofin or IM at
indicated concentrations for 6 hours. Cells were harvested and 50 μg of total protein was
used for each sample assessment. TrxR activity was measured using the TrxR Reductase
Assay Kit (Abcam) per manufacturer's instructions.
ROS Activity Measurement
Cells in log phase of growth were grown to 80% confluence, harvested and aliquoted into 96
well plates at concentrations of 15,000 cells per well in a total volume of 100 μl/well. Cells
were allowed to attach overnight. Cell were preloaded with 2',7'-dichlorodihydrofluorescin
diacetate (DCFH-DA) for 30 min and treated with or without auranofin or IM at indicated
concentrations for 6 hours. ROS activity was measured using the OxiSelectTM Intracellular
ROS Assay Kit (Cell Biolabs, INC) per manufacturer's instructions.
Early Apoptosis Assay
Cells in log phase of growth were grown to 80% confluence, harvested and aliquoted into 6-
well plates at a concentration of 5,000,000 cells per well in a total volume of 5 ml. Cells
were allowed to attach overnight and then were treated with auranofin at different
concentrations (0, 0.2% DMSO, 0.1 and 10 μM) for 24 h. Early apoptosis cells were
detected by the Guava Nexin® Annexin V assay kit using Guava easyCyte™ sampling flow
cytometer (Millipore).
Cell Proliferation and Caspase 3/7 Activity Assay
Cells in log phase of growth were grown to 80% confluence, harvested and aliquoted into
384-well plates at concentrations of 1,000–1,500 cells per well in a total volume of 20 μl/
well using a Matix Wellmate (Thermo Scientific). Cells were allowed to attach overnight
and 5 μl of culture media containing either vehicles or drug were added to each well. Cell
proliferation was evaluated. After reading fluorescence, Caspase-Glo® 3/7 Assay Reagent
(Promega) was used according to manufacturer's instructions. After background subtraction,
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luminescence was measured and quantified by normalizing luminescence to fluorescence.
Caspase 3/7 activity values were expressed as percentage of the mean of the relative vehicle
controls.
Western Blot Analysis
Cells in log phase of growth were grown to 80% confluence, harvested and aliquoted into 6-
well plates at a concentration of 5,000,000 cells per well in a total volume of 5 ml. Cells
were allowed to attach overnight and then were treated with drugs at indicated doses for 6
hours. Whole-cell extract was prepared as described previously (14). Briefly, for each
specimen, 50 μg whole-cell extract was electrophoresed on 10% precast polyacrylamide gel
(Bio-Rad) and transferred onto nitrocellulose membranes. After 1-hour blocking in 5%
bovine serum albumin (BSA) or 5% nonfat milk in TBS/0.1% Tween-20, membranes were
incubated with primary antibodies (1:1,000 or 1:500 dilution) overnight at 4 °C. After
incubation with HRP-conjugated secondary antibody at room temperature for 1 hour,
development was carried out using Immun-Star™ HRP Chemiluminescence Kits (Bio-Rad).
All western blots were performed in triplicate. Phosphorylated proteins were normalized to
total proteins and quantified using Image J (NIH).
Antibodies
The following antibodies were used for Western blot analysis: rabbit anti-c-KIT, rabbit anti-
c-KIT XP®, rabbit anti-phospho-c-KIT (Tyr719), rabbit anti-AKT, rabbit anti-phospho-
AKT (Ser473) XP®, rabbit anti-phospho-AKT (Thr308), mouse anti-ERK1/2, mouse anti-
phospho-ERK1/2 (Thr202/Tyr204) (Cell Signaling technology, MA); mouse anti-β-actin
(Sigma, MO).
Statistics
Data were reported as mean ± SEM of 3–5 independent experiments, each treatment was
performed in duplicate or triplicate. Values were compared using the Student's t test or with
one-way ANOVA when three groups were present. Results were deemed statistical
significant if p < 0.05.
RESULTS
Screening FDA Approved Drugs for Activity in GIST
To identify drugs that might be repurposed for patients with GIST, we used a quantitative
drug screen experimental approach to assess the activity of 796 FDA-approved drugs in
GISTs. The CellTiter-Blue® oxidation-reduction dye is used as an indicator of cell viability.
Prior to the screen, the cell viability assay was miniaturized to a 384-well format to
accelerate assay throughput. For optimization of assay performance, the number of cells/
well and the length of the incubation period, and the volume of CellTiter-Blue reagent were
empirically determined (Table 1). In order to reduce systematic errors such as variation in
incubation time, time drift in measuring different plates, DMSO tolerance and edge effect
were also considered and tested. Our DMSO tolerance assay indicates that the DMSO used
in the screen does not affect cell viability (see supporting material, Figure S1A). In addition,
the edge effect assay indicates that after 5 hours, the signal will have significant reduction in
wells at edge (see supporting material, Figure S1B). Therefore, we controlled reading time
to less than 5 hours for each cell line.
The protocol of the preliminary screening study is summarized in Table 1. A total of 152
plates were screened. The assay performed well over the entire course of the screen as
demonstrated by the Z' values. The averaged signal/background ratio, Z' value and the signal
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window of the control wells for each cell line were summarized in supporting material Table
S2.
Data were normalized as percentage inhibition relative to vehicle control and plotted in a 3-
D plot (Figure 1A) for each plate. Curves were classified into 3 categories (supporting
material Table S3 and Figure 1B, 1C & 1D) and IC50 values were calculated and both of
them were used to define active/inactive drugs. FDA-approved drugs failing to demonstrate
activity were ruled out from the following analysis. IC50 values were calculated for drugs
demonstrating positive inhibition values (IC50 value < 1.0 μM). Typical IC50 curves were
shown in Figure 1E.
Based on drug concentration-response curve quality in the primary screen, 29 drugs showed
preclinical potent in vitro activity (IC50 ≤ 1 μM) against one or more GIST cell lines
including two mutant GIST cell lines (GIST-T1, exon 11 KIT mutation, and GIST 882, exon
13 KIT mutation), and an imatinib resistant variant of T1 cell line (GIST T1-10R, derived in
the Godwin laboratory). The screen results are summarized in Table 2.
Validating Activity of FDA Approved Drugs in GIST
The active compounds from the screen were triaged into 3 groups: active in i) one of the
GIST cell lines, ii) two of the GIST cell lines, or iii) three GIST cell lines (Table 2). The
ideal candidate should have a low IC50 value of < 1.0 μM against three GIST cell lines and a
high IC50 value of > 1.0 μM against the ULTR cell line. However, later we found the data
generated from ULTR cell line are not informative, since these cells were also transformed
(data not shown). Instead, Hs 919.T., a benign osteoid osteoma cell line, was used as the
non-sarcoma cell line control. Drugs were screened at the concentration of 1 μM. The data
are summarized in Table S4 in the supplemental materials. Ten drugs (bortezomib,
doxorubicin, mitoxantrone, idarubicin HCl, digoxin, daunorubicin, vinorelbine, plicamycin,
dactinomycin and mebendazol) showed inhibition against Hs 919.T. cell proliferation
greater than 50% indicating that these drugs have no selectivity against sarcoma and non-
sarcoma cells. Therefore, based on inhibitory activity against three GIST cell lines, and
subsequent drug development and regulatory science gap analysis of each of the 29
screening hits, three drugs (auranofin, bortezomib, and idarubicin) which are active in all
GIST cell lines and one drug (fludarabine phosphate) which is active in IM-resistance cell
line were prioritized for further validation. Pure compounds (> 99% purity) were obtained
and prepared as described in the materials and methods section. In vitro activities of the four
prioritized drugs were evaluated employing 12-point dose-response curves ranging from 20
μM to 1 nM, with triplicate sampling. Typical IC50 curves generated from the validation are
shown in Figure 1F. The structures of the candidate drugs are summarized in Table S5. The
IC50 values and drug selectivity were confirmed and listed in Table 3. The hit validation of
the top candidates was highly reproducible except fludarabine phosphate showed active
across the three GIST cell lines.
Two drugs, auranofin and fludarabine phosphate showed selectivity against GIST cell lines.
One of them, auranofin, has been shown to inhibit TrxR system and has been proposed as a
promising experimental agent for cancer treatment (20, 24, 25). The Auranofin
pharmacological data is listed in Table S6. Auranofin has an acceptable clinical safety
profile (26) and is currently being evaluated in chronic lymphocytic leukemia patients at the
University of Kansas Cancer Center, National Heart, Lung and Blood Institute, and The
Ohio State University Comprehensive Cancer Center (ClinicalTrials.Gov Identifier
NCT01419691). Furthermore, we analyzed a microarray dataset GSE31802 (27) for GIST
tumors and found that the TrxR (all three isoforms TrxR1, TrxR2, TrxR3) are present in
specimens from GIST patients (n=14) with expression of TrxR1 and TrxR3 being 1.2 folds
higher (p value< 0.01) as compared to that of TrxR2 (Figure S2A & S2B). Based on our
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findings, prior human safety experience, as well as activity of this FDA approved drug in
other cancers, we selected auranofin for further mechanistic studies in GIST.
Auranofin Inhibits TrxR Enzymatic Activity in GIST Cells
Gold(I) and gold(III) compounds have been reported to be highly specific inhibitors of
mitochondrial TrxR. It has been shown that gold compounds preferentially interact with a
selenol group in the active site at the C terminus of TrxR since selenol displays a greater
affinity toward heavy metals (28). Mammalian TrxR is a key enzyme for maintenance of the
intracellular reduced environment. Impaired TrxR system will lead to increased levels of
oxidized thioredoxin that will render its ability to protect cells from a variety of oxidative
stresses (28). As such, we hypothesized that TrxR might be a molecular target of auranofin
treatment in GIST cells. To examine whether auranofin treatment affects the TrxR/Trx
system in GIST cells, we compared levels of TrxR activity after auranofin and IM
treatments. Figure 2A shows the effect of a 6-hour auranofin treatment on GIST cells. Only
GIST T1-10R cells showed a significant decrease of TrxR activity at the lower concentration
treatment (0.01 and 0.1 μM). At higher concentrations (1.0 and 10 μM), auranofin
dramatically reduces the TrxR activity in all three GIST cell lines. At auranofin exposures in
cell culture up to 24 hours at 1 μM, TrxR enzymatic activity is inhibited (Figure S3A, B &
C). Compared to auranofin treatments, IM treatments did not change the TrxR activity level
in all three GIST cell lines (Figure 2B).
Auranofin Increases Intracellular ROS Levels in GIST Cells
It is known that all types of cells generate low but detectable amounts of ROS under
different circumstances and that ROS serve as important mediators of redox homeostasis
under physiological conditions. The production of ROS is tightly regulated by antioxidant
systems, which maintain redox homeostasis within the cellular environment. Over-
production of ROS and impaired antioxidant systems (e.g., TrxR system) may lead to
oxidative stress and it is known to contribute to the pathogenesis of several diseases
including cancers (24, 25). It is also known that ROS have distinct functional effects, which
are dependent on a number of factors such as the type of cell within which ROS are
generated, and the local concentration of ROS at subcellular sites where they may modulate
enzyme activity and influence gene expression (29, 30).
The effect of auranofin on the production of ROS in GIST cells is shown in Figure 2C. The
addition of auranofin (1 and 10 μM) strongly stimulates the formation of ROS in GIST-T1
and GIST T1-10R cells (2.4-fold and 2.6-fold changes, respectively, Figure 2C). Compared
to the other two GIST cell lines, GIST 882 cell line did respond to auranofin treatment at the
concentration of 1 and 10 μM but the decrease in the ROS production was relatively lower
(1.5-fold change, Figure 2C). At lower concentrations (0.01 and 0.1 μM auranofin
treatment), ROS remained relatively stable in all three GIST cell lines. As we expected, the
longer treatment with auranofin induces higher production of ROS in all three GIST cell
lines (Figure S3D, E & F), while IM treatment had little effect on ROS (Figure 2D).
Effect of Auranofin on PI3K, AKT and ERK1/2 Pathways in GIST Cells
GIST-T1 and GIST 882 cell lines demonstrate constitutive activation of the AKT and
ERK1/2 pathways and exposure to IM resulted in dephosphorylation of KIT, AKT and
ERK1/2 (14). It has been shown that oxidation of thioredoxin or increased ROS may trigger
the activation of ERK pathway depending on the transient or prolonged activation (31, 32).
Under basal or low oxidative stress, ROS may promote cell survival and proliferation which
leads to cancer development (33). Excessive ROS levels, however, can cause cellular
damage, and even cell death (34). It is also known that the effect of ROS is cell-type
dependent (35–38). In order to understand the mechanism of action of auranofin in GIST
Pessetto et al. Page 7













cells, it is important to identify these molecular components involved in the cascade of
events that finally trigger cell death. Therefore, we examined whether PI3K, AKT and ERK
signaling pathways were involved in auranofin treatment in GIST cells. Our results indicate
the effect of auranofin on PI3K, AKT and ERK signaling pathways in GIST cells is dose-
and cell-type dependent. These observations are consistent with our TrxR and ROS activity
results. Treatments of 0.01 or 0.1 μM auranofin for 6 hours resulted in a basal or low level
of ROS which leads to the increasing of pAKTThr308 levels (~8-fold, ~ 5-fold respectively,
Figure 3B&E) in GIST-T1 cells. When cells were treated with 1 or 10 μM auranofin for 6
hours, which resulted in higher fold changes of ROS production (~2.0-fold-change, Figure
2C) in GIST-T1 cells, p-cKT, pAKTSer473, and pAKTThr308 levels are all decreased (~0.5-
fold change, ~0.5-fold change, and ~0.06-fold-change respectively, Figure 3B&E). Similar
to GIST-T1 cells, GIST T1-10R cells respond to auranofin in a manner related to ROS
levels. Treatments of 0.01 or 0.1 μM auranofin for 6 hours resulted in the increasing
pERK1/2 levels (~3.0-fold and ~3.6-fold changes, Figure 3C&F). Treatments of 1 or 010
μM auranofin for 6 hours resulted in the decreasing of pAKTThr308 levels (~0.6-fold and
~0.4-fold changes, Figure 3C&F) and the increasing pERK1/2 levels (~2.7-fold and ~2.4-
fold changes, Figure 3C&F). GIST 882 cell line generates different levels of ROS and is
more stable compared to vehicle-treated cells across all auranofin treatments (~1.5-fold
change, Figure 2C), therefore, auranofin does not noticeably alter phosphorylated levels of
cKIT, AKT and ERK (Figure 3A&D).
Auranofin Stimulates Early Apoptosis and Caspase 3/7 Activity which Causes Reduction
in Cell Viability in GIST Cells
To test our hypothesis that auranofin treatment in GIST cells inhibits TrxR enzymatic
activity and increases ROS production leading to apoptosis (Figure 3G), we carried out early
apoptosis detection assay using Annexin V staining. The fraction of early apoptotic cells
increased ~4-fold, ~2.8-fold, and ~2.3-fold in GIST-T1, GIST T1-10R and GIST 882 cells
respectively after the 24-h auranofin treatment (1 μM) (Figure S4). To further study the
apoptotic affect by auranofin treatment, we carried out caspase 3/7 activity assays and cell
viability assays. The apoptotic activity of auranofin was evaluated on GIST cells with the
presence of 0.1 and 1 μM auranofin for 72 hours. Auranofin treatment was able to increase
Caspase 3/7 activity (Figure 3H). Caspase 3/7 is responsible for cleavage of cellular proteins
that are characteristically proteolysed during apoptosis. After 72 hour of treatment, the
percentage of living cells was determined and is shown in Figure 3I. As described in Figure
3H, auranofin induced a decrease in cell viability after 1 μM treatment in all three GIST cell
lines. It is very interesting that low-dose auranofin treatment also induced cell proliferation
in GIST-T1 and GIST T1-10R cells (~1.1–1.2 fold, Figure 3I).
DISCUSSION
The drug screening assay described in the present study is robust and meets criteria for
industry-accepted high-throughput screening standards (Z' > 0.5) (Table S2), therefore, this
protocol can easily be applied to higher throughput analysis. Of the 796 FDA-approved
compounds screened, 29 were demonstrated to possess inhibitory properties against one or
more GIST cell lines with an IC50 value equal to or lower than 1 μM. Of these, four
compounds were selected as those representing the most promising starting points for
further validation, since they had activity across both IM-sensitive and -resistant GISTs
(Table 3). Validation confirmed the activity and selectivity of these drugs. The different
results between the primary screen and validation for fludarabine phosphate suggest that the
drug may have been preloaded incorrectly using the Echo550 platform, leading to the initial
under appreciation of its activity in the primary screen.
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One of the hits, auranofin (Ridaura®), is an oral, lipophilic gold-containing compound
approved by the FDA in 1985 for the treatment of rheumatoid arthritis. Auranofin has
multiple cellular effects that contribute to its efficacy as an anti-arthritis agent. It inhibits
TrxR and induces a permeability transition resulting in cytochrome c release from the
mitochondria, leading to apoptotic cell death (29, 38–40). In HL-60 human promyelocytic
leukemia cells, reactive oxygen species (ROS) – induced apoptosis is dependent on p38-
MAPK signaling (41). It also induces G2 cell cycle arrest, consistent with activation of a
DNA damage-responsive checkpoint (42). In addition, auranofin modulates multiple
signaling pathways that are critical to cancer cell survival. It inhibits JAK/STAT signaling,
reducing the levels of the anti-apoptotic protein Mcl-1(30), reduces levels of NF-kB
transactivated anti-apoptotic proteins (30, 43), antagonizes EGF ligand-receptor interactions
(44), and blocks the activity of protein kinase C (45). There is evidence that low levels of
oxidants activate several cell signaling pathways and regulate cell survival and proliferation,
whereas high levels of oxidants stimulate stress-activated signaling pathways leading to cell
death (35–37). However, the effect of ROS is cell type dependent (46). The results of our
experiments show a dose-dependent inhibition of TrxR activity and ROS production in the
auranofin concentration range of 0.01 to 10 μM. The response to auranofin treatment in
GIST cell lines is closely related to the endogenous or inducible ROS level. The results
clearly indicate that early apoptosis was induced by auranofin treatment and caspase 3/7
proteases are activated in response to apoptosis induced by auranofin in all GIST cell lines.
These results provide the preclinical proof-of-principle to explore the use of auranofin in the
oncology setting.
Auranofin is effective and well tolerated in rheumatoid arthritis. In dose titration studies,
auranofin showed activity at doses as low as 2 mg orally daily, with greater efficacy at 6 and
9 mg daily (47–49). Daily doses greater than 6 mg led to more rapid clinical improvement.
The most frequent side effects are diarrhea, rash and pruritis; stomatitis, alopecia and
conjunctivitis (47, 49). Serious, but infrequent, side effects include anemia, leucopenia,
thrombocytopenia, eosinophilia and proteinuria. All are reversible with dose reduction or
discontinuation of therapy. Its safety in pregnant and lactating women has not been
conclusively established. Results from this work are consistent with other investigators
reporting that auranofin has potential anti-cancer effect through induction of apoptotic cell
death in tumor cells (24, 28). Besides its potential anti-cancer activity, recently auranofin
has been reported to have potential amebicidal activity and is being repurposed for the
treatment of amebiasis (50).
The results obtained in this study support the idea that auranofin can induce apoptosis in
GIST cells as a result of inhibition of TrxR and subsequent increases in intracellular levels
of ROS. More importantly, the anti-cancer activity associated with auranofin may be
independent of the mutational status and prior response to imatinib and may be more closely
related to the endogenous and inducible levels of ROS (Figure 2 and data not shown). These
preclinical data provide a strong rationale to evaluate auranofin in patients with treatment-
refractory GIST.
The evaluation of potential new uses for FDA approved represents an opportunity to rapidly
advance to cancer patients, promising drug therapies by capitalizing on existing data and
experience. The same holds true for abandoned or “shelved” drug candidates. There is
growing interest in partnering with innovator firms to potentially evaluate new uses for
“shelved” drugs, the development of which have been “abandoned” due to issues other than
drug safety. Weir, Austin and DeGennaro (20) reported the rapid translation of auranofin in
vitro screening results in primary CLL cell lines directly into a multi-site, clinical proof of
concept trial in chronic lymphocytic leukemia (CLL) patients (ClinicalTrials.Gov Identifier
NCT01419691). As a result of the studies described in this publication, a drug repurposing
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strategy is underway to rapidly translate these findings to GIST patients with recurrent and
metastatic disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Post-HTS analysis. A, data acquisition are shown as a 3-dimensional representation. Plot
was generated from GIST T1-10R cell line. B, C and D, examples of drug concentration-
response curves. Detailed information of curves are summarized in Table S3. E and F, IC50
curves for auranofin derived from the primary screen and derived from the subsequent
validation assays.
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In vitro effects of auranofin or IM treatment on TrxR/Trx system. A and B, auranofin
inhibits thioredoxin reductase (TrxR) activity in GIST cells. IM does not alter TrxR activity.
GIST cells were treated for 6 h with the indicated concentration of auranofin before cells
were harvested and lysed. For each sample, 50 μg of protein cell lysate was assessed for
TrxR activity by measuring NADPH-dependent reduction of DTNB. C and D, auranofin
increases reactive oxygen species (ROS) activity in GIST cells. IM does not increase the
production of ROS. GIST cells in a 96-well plate were pretreated with 1 mM DCFH-DA for
60 minutes at 37 °C. Cells were then treated for 6 h with the indicated concentration of
auranofin. ROS activity was measured using DCF fluorescence. (* p value < 0.05)
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Effect of auranofin or IM treatments on signaling pathways and cell viability. A, GIST 882.
B, GIST-T1; and C, GIST T1-10R cells were treated with auranofin or IM at indicated
concentration for 6 h. For each sample, 50 μg of total protein cell lysate was loaded for
western blots. D, E, and F, Bar graph shows combined densitometric quantification (Image
J) of western blot results. Each bar represents results from two independent experiments. G,
proposed mechanism of auranofin action in GIST cells. Auranofin inhibits TrxR system and
results in increased ROS production which finally leads to apoptosis and cell growth
inhibition. H, Auranofin induces apoptosis in GIST cells. GIST cells in a 384-well plate
were treated for 72 h with or without 0.01 μM or 1 μM of auranofin. Caspase 3/7 activity
was measured by luminescence. F, Auranofin inhibits proliferation of GIST cells. GIST cells
in a 384-well plate were treated for 72 h with or without 0.01 μM or 1 μM of auranofin. (* p
value < 0.05)
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Table 1
Automation protocol for drug repurposing screen.
Step Event Parameter Description Notes
1 Pre-spot librarycompoundsor DMSO 250 nl




2 Add reagent 20 μl
GIST-T1 cells: 1,000 cells/well
GIST 882 and GIST-T1-10R cells: 1,500 cells/well ULTR
cells: 500 cells/well
Instrument: Matrix Wellmate
3 Incubate 72 hrs 5% CO2/37 °C incubation
4 Add reagent 5 μl Promega CellTiter-Blue
5 Incubate 3 hrs 5% CO2/37 °C incubation
6 Read Fluorescence 544 nm Ex/590 nm Em, gain=70. Instrument: Infinite M200 Pro
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Table 2
Drug repurposing for GISTs hits summary.
Group Drug Therapeutic use
IC50 (μM)
GIST-T1 GIST 882 GIST TI-10R ULTR
1
Albendazole Anthelmintic 0.30 > 1.0 > 1.0 0.32
Amsacrine Antineoplastic, immune suppressive 0.31 > 1.0 > 1.0 > 1.0
Mebendazole Anthelmintic 0.81 > 1.0 > 1.0 0.73
Paclitaxel Antineoplastic 0.21 > 1.0 > 1.0 0.20
Vinorelbine Antineoplastic 0.23 > 1.0 > 1.0 0.08
Chloroquine Antimalaria > 1.0 0.46 > 1.0 > 1.0
Cladribine Ant ine op lactic > 1.0 0.76 > 1.0 0.54
Danazol Anterior pituitary suppressant > 1.0 0.67 > 1.0 > 1.0
Etoposide Antineoplastic > 1.0 0.03 > 1.0 > 1.0
Teniposide Antineoplastic > 1.0 0.09 > 1.0 0.19
Fludarabine Phosphate Antineoplastic > 1.0 > 1.0 0.81 > 1.0
2
Clofarabine Antineoplastic, alkylating agent > 1.0 0.99 > 1.0 0.18
Dactinomycin Antineoplastic, alkylating agent 0.07 <0.07* > 1.0 <0.07*
Daunorubicin Antineoplastic <0.07 0.17 > 1.0 <0.07*
Digitoxin Inotropic, cardiotonic <0.16 0.16 > 1.0 <0.07*
Doxorubicin Antineoplastic 0.31 0.08 > 1.0 0.16
Imatinib Antineoplastic 0.18 0.13 > 1.0 > 1.0
Mitoxantrone Antineoplactic 0.42 0.08 > 1.0 <0.07*
Nilotimb Antmeoplactic 0.38 0.10 > 1.0 > 1.0
Plicamycin Atineoplastic antibiotic 0.35 < 0.07* > 1.0 0.15
Topotecan Antineoplastic 0.08 0.44 > 1.0 0.09
3
Auranofin Antirheumatic 0.23 0.38 0.16 0.19
Bortezomib Antimyeloma <0.07* <0.07* 0.50 <0.07*
Carbimazole Antithyroid <0.07* 0.05 0.18 <0.07
Digoxin Cardiac stimulant 0.16 0.79 0.93 0.16
Gentian Violet Antibacterial, anthelmintic 0.52 0.25 0.96 0.16
Idarubicin Antileukemic 0.10 0.05 0.69 <0.07*
Ouabain Antiarrhythmic, cardiotonic, hypertensive, Na/KATPase inhibitor 0.21 0.03 0.24 <0.07
*
Compounds are listed alphabetically and not in order of activity.
Group 1 indicates drug activity (<1 μM) in a single GIST cell lines, Group 2 in two GIST cell lines, and Group 3 in all three GIST cell lines.
*
IC50 < 0.07 μM and drug showed no dose response.
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Table 3
Hit validation, drug structures and IC50 values of validated hits.
Drug IC50
GIST-T1 GIST 882 GIST T1-10R Hs 919.T.
IM 0.06 ± 0.03 0.13 ± 0.02 > 1 *ND
Auranofin 0.25 ± 0.15 0.64 ± 0.18 0.02 ± 0.01 *ND
Bortezomib 0.006 ± 0.002 0.002 ± 0.0003 0.001 ± 0.001 0.15 ± 0.01
Fludarabine Phosphate 0.53 ± 0.04 0.54 ± 0.03 0.84 ± 0.20 *ND
Idarubicin HC1 0.09 ± 0.01 0.13 ± 0.04 0.05 ± 0.01 0.07 ± 0.003
*
ND: drugs showed no dose response.
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